Work

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

Year: 2009

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v114.22.643.643

Authors: Jorge Cortes, Moshe Talpaz, Michael Deininger, Neil Shah, Ian W Flinn, Michael J. Mauro, Thomas O'Hare, Natalie Spinos, Simin Hu, Lori Berk, Narayana Narasimhan, Victor M. Rivera, Tim Clackson, Frank Haluska, Hagop M. Kantarjian

Institutions: The University of Texas MD Anderson Cancer Center, University of Michigan, Oregon Health & Science University, University of California, San Francisco, Howard Hughes Medical Institute, ARIAD Pharmaceuticals (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979325951

FWCI: 5.742

Cites:

Cited by: 32

Related to: 10